Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
Lead Product(s): TI-168
Therapeutic Area: Genetic Disease Product Name: TI-168
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baudax Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 30, 2023
Details:
Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
Lead Product(s): TI-168
Therapeutic Area: Genetic Disease Product Name: TI-168
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023
Details:
TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolerated dose.
Lead Product(s): TI-168
Therapeutic Area: Genetic Disease Product Name: TI-168
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022